SCHEMBL6973608

SCHEMBL6973608

ClCc1cnc(-c2ccccc2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.53
CYP11B2 P19099 2/20 0.53
ALDH1A1 P00352 8/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 7/20 0.45
RAB9A P51151 7/20 0.45
MAPT P10636 3/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 1/20 0.45
LMNA P02545 6/20 0.44
KDM4E B2RXH2 4/20 0.44
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
HPGD P15428 3/20 0.44
CYP1A2 P05177 2/20 0.43
QPCT Q16769 1/20 0.43
HDAC6 Q9UBN7 1/20 0.42
HPGDS O60760 1/20 0.42
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762765 0.83 SMN1; SMN2 (0.49) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL2095827 0.82 CYP11B1 (0.54) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL21753345 0.81 CYP11B1 (0.47) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL27955951 0.81 CYP11B1 (0.37) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL2226354 0.81 CYP11B1 (0.53) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL3492794 0.81 CYP11B1 (0.53) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL28812866 0.81 CYP11B1 (0.65) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL1895825 0.81 CYP11B1 (0.56) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL153089 0.81 CYP11B1 (0.56) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1
SCHEMBL18667423 0.80 CYP11B1 (0.49) CYP11B1CYP11B2ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240270737-A1 SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE STINGINN INC. (US) 2024-08-15 US disclosed
CN-113968799-B Malononitrile compound and application thereof 沈阳化工大学 2023-07-04 CN disclosed
CN-113968799-A Malononitrile compound and application thereof 沈阳化工大学 2022-01-25 CN disclosed
US-20200040025-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE TUFTS UNIVERSITY 2020-02-06 US disclosed
WO-2018058148-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE TUFTS UNIVERSITY (US) 2018-03-29 WO disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed
EP-0665222-A1 Guanidine derivatives, their production and insecticides Takeda Chemical Industries, Ltd. (JP) 1995-08-02 EP disclosed
CN-1026981-C Process for the preparation of guanidine derivatives TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1994-12-14 CN disclosed
CN-1077843-A GUANIDINE DERIVATIVES, THEIR PRODUCTION AND INSECTICIDES TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1993-11-03 CN disclosed
EP-0493369-A1 Guanidine derivatives, their production and insecticides Takeda Chemical Industries, Ltd. (JP) 1992-07-01 EP disclosed
EP-0222576-B1 HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS PFIZER INC. (US) 1992-03-18 EP disclosed
US-5034404-A Nitroguanidines as insecticides TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1991-07-23 US disclosed
CN-1009831-B PROCESS FOR PREPARING HETEROCYCLE-OXO-2,3-DIAZANAPHTHYL-ACETIC ACID PFIZER (US) 1990-10-03 CN disclosed
CN-1045261-A Guanidine derivatives, their production and pesticides TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1990-09-12 CN disclosed
EP-0376279-A2 Guanidine derivatives, their production and insecticides Takeda Chemical Industries, Ltd. (JP) 1990-07-04 EP disclosed
CN-86108308-A Heterocycle oxo-2 guanidine-acetic acid 1987-07-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270737-A1 SMALL MOLECULAR INHIBITORS OF STING SIGNALING COMPOSITIONS AND METHODS OF USE STING1, IRF3, MAVS CYP11B1 3773/4885CYP11B2 3978/4885ALDH1A1 4812/4885
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 CYP11B1 1497/4885CYP11B2 1597/4885ALDH1A1 311/4885
US-20200040025-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE P2RY6, UPP1, UMPS CYP11B1 3232/4885CYP11B2 3228/4885ALDH1A1 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.